AstraZeneca PLC (AZN)
162.70
-2.07
(-1.26%)
USD |
NYSE |
Sep 04, 16:00
163.00
+0.30
(+0.18%)
Pre-Market: 20:00
AstraZeneca Research and Development Expense (Quarterly) : 3.456B for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 3.456B |
| December 31, 2025 | 3.725B |
| September 30, 2025 | 3.529B |
| June 30, 2025 | 3.498B |
| March 31, 2025 | 3.089B |
| December 31, 2024 | 3.538B |
| September 30, 2024 | 3.07B |
| June 30, 2024 | 2.876B |
| March 31, 2024 | 2.699B |
| December 31, 2023 | 2.915B |
| September 30, 2023 | 2.487B |
| June 30, 2023 | 2.571B |
| March 31, 2023 | 2.301B |
| December 31, 2022 | 2.53B |
| September 30, 2022 | 2.362B |
| June 30, 2022 | 2.438B |
| March 31, 2022 | 2.197B |
| December 31, 2021 | 2.415B |
| September 30, 2021 | 2.153B |
| June 30, 2021 | 1.802B |
| March 31, 2021 | 1.637B |
| December 31, 2020 | 1.707B |
| September 30, 2020 | 1.481B |
| June 30, 2020 | 1.384B |
| March 31, 2020 | 1.377B |
| Date | Value |
|---|---|
| December 31, 2019 | 1.494B |
| September 30, 2019 | 1.328B |
| June 30, 2019 | 1.326B |
| March 31, 2019 | 1.232B |
| December 31, 2018 | 2.013B |
| September 30, 2018 | 1.242B |
| June 30, 2018 | 1.331B |
| March 31, 2018 | 1.260B |
| December 31, 2017 | 1.527B |
| September 30, 2017 | 1.369B |
| June 30, 2017 | 1.311B |
| March 31, 2017 | 1.349B |
| December 31, 2016 | 1.511B |
| September 30, 2016 | 1.362B |
| June 30, 2016 | 1.381B |
| March 31, 2016 | 1.428B |
| December 31, 2015 | 1.668B |
| September 30, 2015 | 1.373B |
| June 30, 2015 | 1.404B |
| March 31, 2015 | 1.294B |
| December 31, 2014 | 1.395B |
| September 30, 2014 | 1.332B |
| June 30, 2014 | 1.229B |
| March 31, 2014 | 1.120B |
| December 31, 2013 | 1.239B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| GSK Plc | 2.310B |
| Johnson & Johnson | 3.603B |
| Eli Lilly & Co. | 3.819B |
| Merck & Co., Inc. | 9.229B |
| Novo Nordisk A/S | 1.783B |